symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
EDSA,4.12,0.817094,72586,12415126,0,2.4603-19.669998,-0.11,"Edesa Biotech, Inc.",USD,0001540159,CA27966L1085,27966L108,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.edesabiotech.com,"Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.","Dr. Pardeep  Nijhawan FRCPC, M.D.",Healthcare,CA,16,289-800-9600,100 Spy Court,Markham,ON,L3R 5H6,0.649062,1.64906,https://financialmodelingprep.com/image-stock/EDSA.png,2010-06-21,False,False,True,False,False
